Extended Data Fig. 2: Co-immunoprecipitation of MCL1-BAK and MCL-Bim. | Nature Cancer

Extended Data Fig. 2: Co-immunoprecipitation of MCL1-BAK and MCL-Bim.

From: BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models

Extended Data Fig. 2

MCL-1 protein was co-immunoprecitated from cells treated with increasing concentrations of BRD-810 for the time indicated. Immunoblots were stained for the respective binding partner BAK (A) and BIM (B) and bands were quantified using densitometric analysis. Data is shown as single measurement per timepoint and concentration.

Back to article page